期刊文献+

结直肠癌肝转移的治疗新策略——一场无硝烟的持久战 被引量:2

原文传递
导出
摘要 一、结直肠癌肝转移的现状和思考-初探战场   (一)结直肠癌肝转移的发病现状与特点-难以攻克的“碉堡”   结直肠癌( colorectal cancer , CRC )仍然是人类最常见的恶性肿瘤之一,据统计,2010年全球新发病例约为120万例,居恶性肿瘤第三位;而同年死亡60.8万例,仍是人类健康的重大威胁[1];初次接诊时大约有20%~25%的新病例为已经伴有结直肠癌肝转移(colorectal liver metastasis,CLMs),而那些接受根治性治疗的患者,将有大约三分之一的病例最终会出现疾病转移、复发而成为晚期[2],即在所有CRC中大约50%的患者最终属于 CLMs;可见CLMs是一个庞大的群体,由于转移复发的程度、范围和累及的器官不同, CLMs的预后、治疗目的和手段也表现各异。面对这一威胁人类健康的巨大病魔,人类发起了一场全球性攻克CLMs的持久战役。
出处 《中华结直肠疾病电子杂志》 2014年第2期57-60,共4页 Chinese Journal of Colorectal Diseases(Electronic Edition)
  • 相关文献

参考文献4

二级参考文献140

  • 1钟芸诗,许剑民,韦烨,任黎,赖衍翰,樊嘉,周俭,钦伦秀,秦新裕.结直肠癌肝转移的外科手术治疗[J].中华肝胆外科杂志,2007,13(2):104-107. 被引量:12
  • 2[82]Saltz L,Rubin M,Hochster H.Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR).Proceedings of the American Society of Clinical Oncology; 2001 May 12-15,San Francisco CA,USA.Vol 20 (3a),Abstract 7
  • 3[83]Vincenzi B,Santini D,Russo A,Silletta M,Gavasci M,Battistoni F,Di Cuonzo G,Rocci L,Gebbia N,Tonini G.Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.Ann Oncol 2006; 17:835-841
  • 4[84]Chong G,Cunningham D.The role of cetuximab in the therapy of previously treated advanced colorectal cancer.Semin Oncol 2005; 32:S55-S58
  • 5[85]Chung KY,Saltz LB.Antibody-based therapies for colorectal cancer.Oncologist 2005; 10:701-709
  • 6[86]Green LL.Antibody engineering via genetic engineering of the mouse:XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies.J Immunol Methods 1999; 231:11-23
  • 7[87]Peeters M,Van Cutsem E,Siena S,et al.A phase 3,multicenter,randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts)with metastatic colorectal cancer (mCRC).Proceedings of the American Association for Cancer Research (AACR); 2006 Apr 1-5; Washington DC,USA.Abstract CP-1.Available from URL:http://aacr/org
  • 8[88]Tournigand C,Andre T,Achille E,Lledo G,Flesh M,Mery-Mignard D,Quinaux E,Couteau C,Buyse M,Ganem G,Landi B,Colin P,Louvet C,de Gramont A.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:a randomized GERCOR study.J Clin Oncol 2004; 22:229-237
  • 9[89]Goldberg RM,Sargent DJ,Morton RF,Fuchs CS,Ramanathan RK,Williamson SK,Findlay BP,Pitot HC,Alberts SR.A randomized controlled trial of fluorouracil plus leucovorin,irinotecan,and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J Clin Oncol 2004; 22:23-30
  • 10[90]Colucci G,Gebbia V,Paoletti G,Giuliani F,Caruso M,Gebbia N,Carteni G,Agostara B,Pezzella G,Manzione L,Borsellino N,Misino A,Romito S,Durini E,Cordio S,Di Seri M,Lopez M,Maiello E,Montemurro S,Cramarossa A,Lorusso V,Di Bisceglie M,Chiarenza M,Valerio MR,Guida T,Leonardi V,Pisconti S,Rosati G,Carrozza F,Nettis G,Valdesi M,Filippelli G,Fortunato S,Mancarella S,Brunetti C.Phase Ⅲ randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer:a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.J Clin Oncol 2005; 23:4866-4875

共引文献43

同被引文献9

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部